Search Results - "Jauch‐Lembach, J."

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches by Blauvelt, A., Lacour, J.‐P., Fowler, J.F., Weinberg, J.M., Gospodinov, D., Schuck, E., Jauch‐Lembach, J., Balfour, A., Leonardi, C.L.

“…Summary Background Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar…”
Get full text

A0532 - Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies by Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.

Get full text

Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies by Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.

Get full text

Updated Findings and Biomarker Analysis From the Ongoing Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors by Papadopoulos, K.P., Gutierrez, M., Duska, L.R., Gandhi, L., Bommi-Reddy, A., Adams, E., Jauch-Lembach, J., Rasco, D.W.

Get full text